ACOG Alpha Cognition Inc.: Company Value to Revenue Ratio

Public company logo of Alpha Cognition Corp (ACOG)

Stable supplies through proven distributors minimize inventory risks. The current EV/Sales trend on the GURU.Markets chart demonstrates a cost balance, where the value of 7509.90 shows the latest figure. The Alpha Cognition (ACOG) model relies on outsourcing production and marketing, while the final business valuation is based on patent protection and FDA approval of new Alzheimer's disease therapies.

ACOG Alpha Cognition Corp: Company Value to Revenue in the range 11/23/2025 - 11/19/2026

ACOG (Alpha Cognition Corp): analytical breakdowns and indicator data

- stock value and consensus price forecast:
Initial company analysis:Alpha Cognition Inc, ACOG
Original product of Alpha Cognition Inc

This ratio compares the total enterprise value to sales volume, providing a real-time assessment of revenue revaluation. The metric allows for the identification of undervalued assets by eliminating distortions caused by debt load. For Alpha Cognition (ACOG), this calculation demonstrates the capitalization of innovations in Alzheimer's disease therapy. The trend of the company's EV/Sales multiple helps define the boundaries of fair value. By analyzing the EV/Sales multiple of Alpha Cognition (ACOG), an investor can recognize a value trap in a timely manner.

Competitor analysis for Alpha Cognition

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Harmony Pharma HRMY|BHVN: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - EV/Sales Multiple|Company Value to Revenue Ratio PRAX (Praxis Medicines)|Enterprise Value-to-Revenue Ratio Anavex Life Sciences (AVXL)|Enterprise Value-to-Revenue Ratio CBLL (CeriBell EEG)|EV/Sales Multiple PRTA (Prothena Corp)|alector.com (ALEC) - Enterprise Value-to-Revenue Multiple|ANNX: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Omeros|NGNE: EV/Sales Multiple|Company Value to Revenue AC Immune|Company Value to Revenue VYGR|Company Value to Revenue Ratio NMRA (neumoratx.com)|Company Value to Revenue SCLX (Scilex Holding Company, Inc.)|Enterprise Value-to-Revenue Ratio TVGN (Tevogen Bio)|EV/Sales Multiple CGTX (cogrx.com)|Total Company Value-to-Revenue Ratio Inhibikase Pharma (IKT)|SAVA: Company Value to Revenue|Total Company Value-to-Revenue Ratio Assertio ASRT|COYA (coyatherapeutics.com) - Company Value to Revenue|Company Value to Revenue Ratio VTGN|OVID (Ovid Therapeutics) - EV/Sales Multiple|Acumen Pharmaceuticals, Inc (ABOS) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio CervoMed, Inc. (CRVO)|ATHE - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple CLNN (Clene Inc.)|Total Company Value-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Relmada Corp|ANVS (Annovis Bio, Inc.) - Company Value to Revenue|Grace Tx (GRCE) - EV/Sales Multiple|Company Value to Revenue AIFF|EV/Sales Multiple anewmeds.com|Enterprise Value-to-Revenue Ratio NeuroSense Therapeutics (NRSN)|RVPH (Reviva Pharmaceuticals Holdings) - Business Value to Revenue|MetaVia - Company Value to Revenue|NRXS: Company Value to Revenue Ratio|Helius Medical Technologies, Inc. - EV/Sales Multiple|PASG: Enterprise Value-to-Revenue Ratio|Neuphoria (NEUP) - Enterprise Value-to-Revenue Ratio|Minerva Neurosciences - Business Value to Revenue|ATHA (Athira Pharma, Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple addextherapeutics.com ADXN|Company Value to Revenue ALZN (Alzamend Neuro Inc.)|CYCN (Cyclerion Therapeutics, Inc.) - Business Value to Revenue|EV/Sales Multiple PTIX (Protagenic)|EV/Sales Multiple pasitheaclinics.com KTTA|CRGT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ATXI (Avenue Therapeutics)|BCLI: EV/Sales Multiple|Cara Therapeutics - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Chromocell Therapeutics Corporation|EV/Sales Multiple Eliem Therapeutics Inc.|Enterprise Value-to-Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Business Value to Revenue|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE